World

Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 10/11/2026, 20:25:25 UTC.

Briefings

The US Food and Drug Administration ordered Ozempic, Wegovy, and other GLP-1 weight-loss drugs to include warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause blindness. This regulatory action follows a 2026 update where the FDA identified a link between these medications and NAION, prompting a mandatory label update for all affected products.

Key points

• The US Food and Drug Administration ordered Ozempic, Wegovy, and other GLP-1 weight-loss drugs to include warnings about non-arteritic anterior ischemic optic neuropathy (NAION).
• The FDA identified a link between these medications and NAION, prompting a mandatory label update for all affected products.

Context

The US Food and Drug Administration ordered Ozempic, Wegovy, and other GLP-1 weight-loss drugs to include warnings about non-arteritic anterior ischemic optic neuropathy (NAION). This regulatory action follows a 2026 update where the FDA identified a link between these medications and NAION, prompting a mandatory label update for all affected products.

Limitations

Evidence is limited to the 2026 FDA announcement regarding NAION warnings for specific GLP-1 drugs. No specific patient data, clinical trial results, or geographic impact statistics are provided in the source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 11/11/2026, 11:01:12 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeic5b2n44uxpfikp6ikbymwga6j3z37yzbqrd37zafrf3q4w2kyoei